CinCor Pharma Inc.

08/08/2022 | Press release | Distributed by Public on 08/08/2022 05:05

CinCor Pharma Announces Positive Topline Data for Phase 2 BrigHtn Trial Evaluating Baxdrostat, its Selective Aldosterone Synthase Inhibitor, in Treatment-Resistant Hypertension